Beloranib
bestPWS
Zafgen · Phase 3 · Terminated · Enrollment 108
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo | n/r | n/r | n/r | n/r |
| ZGN-440 Injectable Suspension (1.8 mg) | n/r | n/r | n/r | n/r |
| ZGN-440 Injectable Suspension (2.4 mg) | n/r | n/r | n/r | n/r |
Not shown
- Placebo: endpoint not reported
- ZGN-440 Injectable Suspension (1.8 mg): endpoint not reported
- ZGN-440 Injectable Suspension (2.4 mg): endpoint not reported